Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Slides:

Advertisements

Similar presentations

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

Advertisements

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.

Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Successful CTO PCI Associated with Lower Mortality Risk

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Glenn N. Levine et al. JACC 2016;68:

Mean eGFR among survivors after CABG surgery vs all-cause deaths

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy Eric J. Velazquez, MD,

Defining operative mortality: Impact on outcome reporting

Why surgery won the SYNTAX trial and why it matters

Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS

Coronary revascularisation rate (total 5

Figure 4 Observational studies on multiple treatment strategies

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

For everything there is a season

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Sara L. Zettervall, MD, MPH, Dominique B. Buck, MD, Peter A

Nat. Rev. Cardiol. doi: /nrcardio

To bypass or stent? The changing rules of an advancing game

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Inflammatory response and CD34+CD45− cell release following percutaneous coronary intervention (PCI). Inflammatory response and CD34+CD45− cell release.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Correlations of calibrated integrated backscatter (cIB) with log10 plasma soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) (A), and log10.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Leslee J. Shaw et al. JIMG 2010;3:

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Davide Capodanno et al. JCIN 2009;2:

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Forest plot illustrating the risk ratio of major bleeding

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment strategies (p<0.001). Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment strategies (p<0.001). CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention. Per Mølstad et al. Open Heart 2016;3:e000489 ©2016 by British Cardiovascular Society